Glenmark Pharmaceuticals Inc., USA has been granted final approval by the United States Food & Drug Administration (USFDA) for Triamcinolone Acetonide Ointment USP, 0.1%, the generic version of Kenalog Ointment, 0.1%, of Mylan Pharmaceuticals Inc.
According to IMS Health sales data for the 12 month period ending June 2017, the Kenalog Ointment 0.1% achieved annual sales of approximately $26.3 million.
Glenmark’s current portfolio consists of 122 products authorized for distribution in the US marketplace and 64 ANDA’s approvals are pending with the USFDA.
Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). The company's geographical segments include India, United States, Latin America, Europe and Rest of the World (ROW).
Get the daily HNI Commodity Pack and more click here @ http://www.ripplesadvisory.com @
No comments:
Post a Comment